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Brain metastases remain a significant challenge in the
treatment of breast cancer patients due to the unique
environment posed by the central nervous system. A
better understanding of the biology of breast cancer
cells that have metastasized to the brain is required to
develop improved therapies. A recent Proceedings of
the National Academy of Sciences article demonstrates
that breast cancer cells in the brain microenvironment
express γ-aminobutyric acid (GABA)-related genes,
enabling them to utilize GABA as an oncometabolite,
thus gaining a proliferative advantage. In this viewpoint,
we highlight these findings and their potential impact
on the treatment of breast cancer brain metastases.metastatic primary breast cancer cells already express
proteins that are essential for the establishment of brainBreast cancer brain metastases represent a
clinically unmet need and are poorly understood
Breast cancer brain metastases (BCBMs) are an increa-
singly common occurrence and portend a poor progno-
sis [1]. Treatment of BCBMs represents an unmet
medical need as there are currently no approved thera-
pies aside from surgical resection and cranial radiation
[2]. Limited systemic treatment options for BCBMs are
due, in part, to the unique challenges posed by the
neural environment. Protection afforded by the blood-
brain barrier produces an immune-privileged sanctuary
and prevents many systemic therapies from penetrating
the brain, affording cancer cells unique opportunities to
flourish within the neural environment. The added com-
plication of drug delivery to BCBMs coupled with our* Correspondence: carey_anders@med.unc.edu
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2014poor understanding of the factors unique to BCBM
growth, metabolism, and stromal interactions continues
to hinder the development of effective therapeutic
strategies.
Two major questions regarding BCBMs are (1) what
factors optimize BCBM cells to seed and survive in the
brain microenvironment, and (2) whether the factors are
present in the primary breast cancer cells or are ac-
quired during metastasis. Among the breast cancer sub-
types, HER2-enriched (HER2+) and triple-negative
primary tumors show higher rates of brain relapse rela-
tive to hormone receptor-positive tumors [3,4], suggest-
ing that some innate feature(s) of primary tumor cells
may dictate the development of brain metastases. Recent
literature suggests that, prior to reaching the brain, some
metastases, including serpins [5], matrix metallopro-
teases [6,7], and αB-crystallin [8]. Once in the brain, re-
cent studies have shown BCBM cells transform the
surrounding glia and neurons to create a more permis-
sive microenvironment [9-11]. Of note, tumor-activated
astrocytes have been shown to play a chemo-protective
role for brain metastases [9] and enhance cancer cell
proliferation and survival [6,12]. Targeting reactive astro-
cytes in the tumor microenvironment yields therapeutic
benefit in vivo by decreasing cancer cell seeding growth
in the brain [13,14]. Thus, current evidence suggests that
BCBMs are the result of both primed breast cancer cells
as well as adaptation to and alteration of the brain-
tumor microenvironment. Better understanding of the
brain microenvironment and its interactions with breast
cancer cells are critical for the development of improved
treatments for BCBMs.ntral Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
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metabolic adaptation to the unique brain
microenvironment
A recent elegant study by Neman and colleagues [15] in-
vestigated whether human BCBMs develop from primed
cells in the primary tumor, or if surviving metastatic
cells adapt to the brain’s unique microenvironment.
The authors compare triple-negative and HER2+ primary
breast tumors, brain metastases, and representative
human-derived cell lines. Relative to both primary tumors
and cell lines, the brain metastases exhibit increased
expression of several components related to signaling
of the inhibitory neurotransmitter γ-aminobutyric acid
(GABA), including GABAA receptors, GABA transporters
(vesicular GABA transporter, GABA transporter 1-3,
GABA-betaine transporter, and glutamate decarboxylase),
and GABA transaminase. The study demonstrates that
upregulation of GABA-related proteins enables increased
transport and metabolism of GABA in BCBMs cells,
thereby increasing cell proliferation. The BCBMs cells also
acquire features of GABAergic interneurons, expressing
interneuron-specific markers like parvalbumin and reelin,
characteristics not seen in the primary tumors.
Future treatments should target the permissive
brain microenvironment and the resulting
adaptations in addition to breast cancer cells
themselves
This work represents one of the few studies that directly
compares human primary breast tumors with brain me-
tastases (rather than assessing brain metastases alone
and/or breast cancer cell lines in vitro or in mouse
models) to identify novel factors involved in BCBM bio-
logy. These results also add to a growing body of evi-
dence showing a ‘breast-to-brain’ transition with cancer
cells adapting to the unique brain microenvironment
and acquiring neuronal characteristics that are not seen
at either the primary and/or other non-brain metastatic
sites [16]. The possibility remains, however, that a small
population of ‘seed’ cells in primary tumors are primed
for brain metastases with additional adaptations that
occur in the brain microenvironment ‘soil’ [17,18].
The acquisition of a novel, neuronal-like GABA shunt
metabolism by the BCBM cells is one of the most
groundbreaking findings of Neman and colleagues’ art-
icle. Cancer cells can exhibit a glycolytic, Warburg-like
metabolism instead of oxidative phosphorylation as seen
in normal tissues [19]; the GABA shunt in BCBMs re-
flects yet another metabolic and proliferative advantage
utilized by breast cancer cells within the neural environ-
ment by providing additional energy through generation
of nicotinamide adenine dinucleotide. This acquired
metabolism may provide a unique target for brain me-
tastases using therapies that inhibit GABA metabolism.Notably, several inhibitors of GABA are approved in the
clinical setting for treatment of epilepsy [20]; however,
careful research is required to determine whether selec-
tively targeting this oncometabolite in the setting of
BCBM will be safe and effective. Additionally, in vivo
modeling of GABA metabolism in BCBMs is needed to
further establish this adaptive response in the context of
a full organism. Ultimately, the work presented by
Neman and colleagues places us one step closer to suc-
cessful therapeutic strategies targeting not only breast
cancer cells themselves, but also the supporting brain
microenvironment, with the goal of improving survival
for patients with BCBM.
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